Research spans oncology and immuno-oncology, integrating phosphoproteomics and bioinformatics to map resistance pathways and rational drug combinations. Develops clinical biomarkers and decision tools, and evaluates nanomedicine safety and delivery to improve efficacy and patient outcomes.